Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease ...

Clinical validation of stem cell reactivation approach positions Pelage as leader in regenerative medicine and aging ...

SANTIAGO DE COMPOSTELA, Spain & SHANGHAI, China I June 17, 2025 I SunRock Biopharma and Escugen have joined forces in a strategic partnership to ...

Interim data on the cancer treatment shows robust potential for balancing efficacy and safety. TAIPEI, Taiwan and SHANGHAI, China and SAN FRANCISCO, CA, USA I June 17, 2025 I Foll ...

SOUTH SAN FRANCISCO, CA, USA I June 16, 2025 I Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome ...

I Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the ...

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of ...

First patient dosed with Debiopharm’s first-in-class CD37 targeted antibody drug conjugate (ADC) in a Phase 1/2, multicenter, open-label trial, for patients ...

Independent Data Monitoring Committee (DMC) has approved continuation of trial as planned with no modifications ...

ROCKVILLE, MD and CAMBRIDGE, MA, USA I June 16, 2025 I Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today ...

MILAN, Italy I June 16, 2025 I AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and ...

New data show clinical safety and early efficacy of SANA, a first-in-class compound that targets creatine-dependent thermogenesis ...